This is why CONMED Corporation (CNMD) Stock is one of the options for the Longer run

At the time of writing, CONMED Corporation [CNMD] stock is trading at $107.27, up 8.04%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CNMD shares have gain 11.58% over the last week, with a monthly amount glided 19.52%, and seem to be holding up well over a long-time horizon.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


On 2, February 2023, CONMED Corporation Announces Fourth Quarter and Full-Year 2022 Financial Results. In a post published today on Yahoo Finance, CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2022.

From an analyst’s perspective:

CONMED Corporation [NYSE: CNMD] stock has seen the most recent analyst activity on October 12, 2022, when Jefferies initiated its Hold rating and assigned the stock a price target of $85. On October 06, 2021, upgrade upgraded it’s rating to Buy but maintained its price target of $150 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $160 on July 15, 2021. Barclays initiated its recommendation with a Overweight and recommended $175 as its price target on May 25, 2021. Needham downgraded its rating to Hold for this stock on November 26, 2019. In a note dated November 12, 2019, JP Morgan initiated an Overweight rating and iterated a target price of $136 on this stock.

For the past year, the stock price of CONMED Corporation fluctuated between $71.09 and $155.51. Currently, Wall Street analysts expect the stock to reach $108.00 within the next 12 months. CONMED Corporation [NYSE: CNMD] shares were valued at $107.27 at the most recent close of the market. An investor can expect a potential return of 0.68% based on the average CNMD price forecast.

Analyzing the CNMD fundamentals

According to CONMED Corporation [NYSE:CNMD], the company’s sales were 270.0 billion in the recent quarter, which represents an 10.60% jump. Gross Margin for this corporation currently stands at +53.02% with Operating Margin at +11.46%, Pretax Margin comes in at +7.19%, and Net Margin reading is +6.16%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 102.24 points at the first support level, and at 97.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 110.34, and for the 2nd resistance point, it is at 113.41.

CONMED Corporation [CNMD] reported earnings per share of $0.77 for its fiscal quarter that ended on 9/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.75/share, meaning a difference of $0.02 and a surprise factor of 2.70%. By comparison, the stated earnings for the previous quarter ended on 6/29/2022 were $0.76 per share as compared to estimates of $0.75 per share, a difference of $0.01 representing a surprise of 1.30%.

Ratios To Look Out For

It is important to note that CONMED Corporation [NYSE:CNMD] has a current ratio of 2.80. Further, the Quick Ratio stands at 1.16, while the Cash Ratio is 0.11. Considering the valuation of this stock, the price to sales ratio is 4.49, the price to book ratio is 5.30.

Transactions by insiders

Insider trading, which has resulted in 2 insider purchases of 4,524 shares and 3 insider sales of 10,000 shares in the past three months, is now the topic of our analysis. Recent insider trading involved Garner Todd W, Executive Vice President & CFO, that happened on Dec 09 when 4500.0 shares were sold. President, CEO and Chair, Hartman Curt R completed a deal on Sep 15 to sell 3500.0 shares. Meanwhile, VP GM Advanced Surgery Peters Stanley W III sold 7500.0 shares on Aug 12.